Literature DB >> 1709153

Phase II trial of 5,6-dihydro-5-azacytidine in pleural malignant mesothelioma.

H M Dhingra1, W K Murphy, R J Winn, M N Raber, W K Hong.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1709153     DOI: 10.1007/bf00194548

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  7 in total

1.  Phase II study of 5,6-dihydro-5-azacytidine in extensive, untreated non-small cell lung cancer.

Authors:  P Y Holoye; H M Dhingra; T Umsawasdi; W K Murphy; D T Carr; J S Lee
Journal:  Cancer Treat Rep       Date:  1987-09

2.  Fetal hemoglobin gene activation in a phase II study of 5,6-dihydro-5-azacytidine for bronchogenic carcinoma.

Authors:  B I Carr; S Rahbar; J H Doroshow; D Blayney; D Goldberg; L Leong; Y Asmeron
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

3.  A phase I and pharmacokinetic study of dihydro-5-azacytidine (NSC 264880).

Authors:  G A Curt; J A Kelley; R L Fine; P N Huguenin; J S Roth; G Batist; J Jenkins; J M Collins
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

4.  Synthesis and antitumor activity of dihydro-5-azacytidine, a hydrolytically stable analogue of 5-azacytidine.

Authors:  J A Beisler; M M Abbasi; J A Kelley; J S Driscoll
Journal:  J Med Chem       Date:  1977-06       Impact factor: 7.446

Review 5.  Malignant mesothelioma 1982: review of 4710 published cases.

Authors:  G Hillerdal
Journal:  Br J Dis Chest       Date:  1983-10

6.  Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients.

Authors:  M R Law; A Gregor; M E Hodson; H J Bloom; M Turner-Warwick
Journal:  Thorax       Date:  1984-04       Impact factor: 9.139

7.  Diffuse malignant mesothelioma. Prospective evaluation of 69 patients.

Authors:  A P Chahinian; T F Pajak; J F Holland; L Norton; R M Ambinder; E M Mandel
Journal:  Ann Intern Med       Date:  1982-06       Impact factor: 25.391

  7 in total
  1 in total

1.  An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.

Authors:  G Falkson; M Hunt; E C Borden; J A Hayes; C I Falkson; T J Smith
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.